Epigenetic age acceleration associated with increased pancreatic disease risk in UK Biobank cohort
In 326,873 UK Biobank participants, two measures of biological age acceleration (KDMAgeAccel and PhenoAgeAccel) were associated with increased risk of pancreatic diseases. The highest acceleration group (G4) had 1.7–3.6 times higher hazard ratios across pancreatic outcomes compared to the lowest group (G1), with the strongest associations for chronic pancreatitis (HR 3.551). Circulating lipid biomarkers partially mediated these associations, accounting for 6–9% of the effect.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 15, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 326,873
- Duration
- —
- Population
- Adults recruited to UK Biobank in 2006-2010
- Primary outcome
- Association between biological age acceleration and pancreatic disease risk
- Effect size
- PhenoAgeAccel G4 vs G1 for all pancreatic diseases: HR 1.706 (95% CI 1.513-1.923); acute pancreatitis: HR 1.637 (95% CI 1.352-1.981); chronic pancreatitis: HR 3.551 (95% CI 2.248-5.609); pancreatic cysts: HR 1.547 (95% CI 1.128-2.122); pancreatic cancer: HR 1.387 (95% CI 1.123-1.713); pancreas-related mortality: HR 1.442 (95% CI 1.139-1.824)
- Significance
- Significant
- Journal
- The journal of nutrition, health & aging
- Published
- Sep 15, 2026
Sources
Primary source
- The journal of nutrition, health & aging ↗Peer reviewed
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.